On December 14, the Exec VP, Chief Bus. Officer of Evoke Pharma (EVOK), Matthew D’onofrio, sold shares of EVOK for $134.1K.
In addition to Matthew D’onofrio, one other EVOK executive reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $6.06 and a one-year low of $0.79. EVOK’s market cap is $77.85 million and the company has a P/E ratio of -5.90. Currently, Evoke Pharma has an average volume of 147.28K.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D’Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
